Form D · Biotechnology
Elicio Therapeutics, Inc.
Boston, MA · CIK 0001601485
Offering snapshot reported Mar 29, 2024 · SEC filing
- Reported sold
- $6M Offering amount: $6M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 19, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 29, 2024 | Initial | $6,000,000 | No comparison | 1 | SEC filing |
| Jan 5, 2024 | Initial | $7,047,530 | No comparison | 1 | SEC filing |
| Jun 23, 2020 | Initial | $6,695,000 | No comparison | 54 | SEC filing |
| Jan 27, 2020 | Initial | $1,000,000 | No comparison | 7 | SEC filing |
| Jan 13, 2020 | Initial | $6,081,980 | No comparison | 51 | SEC filing |
| Jul 17, 2018 | Initial | $15,379,000 | No comparison | 133 | SEC filing |
| Jul 17, 2018 | Initial | $5,438,891 | No comparison | 18 | SEC filing |
| Feb 20, 2015 | Initial | $4,356,452 | No comparison | 23 | SEC filing |
Offering details
- Securities
- Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-509031
Source: Form D, filed Mar 29, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Julian Adams | Director |
| Carol Ashe | Director |
| Yekaterina Chudnovsky | Director |
| Robert Connelly | Director, Executive |
| Peter De Muth | Executive |
| Victor Ganzi | Director |
| Itzhak D. Goldberg | Director, Executive |
| Christopher Haqq | Executive |
| Allen Nissenson | Director |
| Gil Omenn | Director |
| Brian Piekos | Executive |
| Robert Ruffolo | Director |
| Jay Venkatesan | Director |
| Karen Wilson | Director |
| Michael Yamin | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
451 D Street, 5 Th Floor
Boston, MA, 02210
Boston, MA, 02210